|
Online View
|
|
|
|
Accelerating Switchable and
Modular CAR-T Research
with Premium Proteins
|
|
|
|
Switchable and modular CAR-T therapies, now in IND-cleared clinical trials for autoimmune diseases and solid tumors, represent a transformative advance in cell therapy. By utilizing adapter molecules to guide CAR-T cells to specific antigens, this approach enables external control, flexible multi-targeting, and enhanced safety. Compared to traditional CAR-T, it reduces off-target effects, offering greater adaptability across both hematologic and solid malignancies. Sino Biological offers a comprehensive portfolio of switchable and modular CAR-T development solutions, featuring newly launched, endotoxin-free recombinant proteins such as B7-H3, BCMA, and HER2 to accelerate your research with high purity and consistency.
|
|
Learn More about Premium Proteins for Switchable and Modular CAR-T 
|
|
|
|
Comparison between conventional CAR and modular (universal) CAR designs
Source: Mohammad et al. (2024), doi: 10.3389/fimmu.2024.1409665.
|
|
|
|
Why Choose SignalChem Biotech?
|
|
Validated Activity & High Purity
|
|
Endotoxin-Free Proteins Avaliable
|
|
Highly Cited in Reputable Journals
|
|
|
Featured Products
|
|
Human B7-H3 Protein (ECD, His Tag), Activity-validated, Endotoxin-Free
Cat#: 11188-H08H-UE
|
|
High Purity
|
|
Bioactivity verified by ELISA
|
|
|
|
|
|
≥ 90% as determined by SDS-PAGE & SEC-HPLC
|
|
Immobilized Enoblituzumab-Derived anti-Human B7H3 antibody can bind Human B7-H3 Protein (Cat#: 11188-H08H-UE)
|
|
|
|
Human BCMA Protein (ECD, rFc Tag),
HPLC-verified
Cat#: 10620-H15H
|
|
Human Her2/ERBB2 Protein (ECD, hFc Tag), HPLC-verified, 80 Citations
Cat#: 10004-H02H
|
|
High Bioactivity
|
|
High Bioactivity
|
|
|
|
|
|
Immobilized Human BCMA Protein (rFc Tag) at 2μg/mL (100 μl/well) can bind Human BLyS Protein (Fc & AVI Tag) (Cat#: 10056-H42H-B) (QC tested).
|
|
Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation.
|
|
|
Click to View More Recombinant CAR-T Target Proteins
|
|
|
|
View Modular CAR-T Therapy Target Poster
|
|
• Advantages of Modular CAR Technology
• Summary of FDA-Approved CAR-T cell therapies
• Application of Recombinant Proteins in CAR-T Therapy Development
|
|
Download Poster Now >>
|
|
|
|
|
Don’t Miss Out!
|
|
|
|
Kinase Drug Discovery Solutions >>
|
|
Center for Bioprocessing (C4B)
US-Based Recombinant Production >>
|
|
|
|
|
